CIPRO XL DIN 02247916
Status: Cancelled Post Market
Holder: BAYER INC
Health Canada record
| Active ingredient(s) | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN) 500 MG |
|---|---|
| Dosage form | Tablet (Immediate- And Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01MA02 CIPROFLOXACIN |
| Original market date | 07-Aug-2003 |
| Current status date | 01-Mar-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bayer Inc — licence 101029, currently licensed, last inspection rating C (2023-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02416484 | MYLAN-CIPROFLOXACIN XL | MYLAN PHARMACEUTICALS ULC | Tablet (Extended-Release) | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN) 1000 MG | Cancelled Pre Market |
| 02416433 | PMS-CIPROFLOXACIN XL | PHARMASCIENCE INC | Tablet (Immediate- And Extended-Release) | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN) 500 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 20147 | 2017-12-11 | Supplement to a New Drug Submission (SNDS) | UPDATE THE PRODUCT MONOGRAPH WITH REVISED INDICATIONS SECTIONS |
| 19348 | 2017-05-25 | Supplement to a New Drug Submission (SNDS) | TO UPDATE THE PRODUCT MONOGRAPH AS PART OF CLASS LABELLING CHANGES FOR ALL FLUOROQUINOLONES WITH RESPECT TO PERMANENT DISABILITIES |
| 357 | 2003-08-07 | New Drug Submission (NDS) |